Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ursodiol 500mg Formulations
NCT03512808Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2017
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ursodeoxycholic acid in primary biliary cholangitis (PBC) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Started Jun 2017; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03512808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512808.